HB1011
Asset
Allogeneic myocardium-derived mesenchymal stem cells to repair and regenerate damaged heart muscle
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Stem cell maintenance
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Ischemic cardiomyopathy
Phase 1, Recruiting, NCT07861035, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.